Please ensure Javascript is enabled for purposes of website accessibility

3 Reasons Why Celgene Corp.'s Stock Dropped 15% in January

By George Budwell - Feb 9, 2016 at 9:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Celgene took a bath in January, and not just because the market was shying away from all things biotech.

CELG Chart

CELG data by YCharts

What: The blue-chip biotech Celgene Corp. (CELG) lost nearly 15% of its value last month, according to data provided by S&P Global Market Intelligence. Celgene's stock was walloped by the changing market sentiment toward biotechs in general, a disappointing annual outlook issued by management to kick off the month, and finally, a rare fourth-quarter earnings miss to end the month.

So what: In many ways, Celgene is a bellwether stock for the whole biotech industry. Not only is it a major component of the iShares Nasdaq Biotechnology ETF (IBB 0.39%), but investors have tended to look toward this particular name as a key pacesetter in terms of revenue growth and innovation.

Source: Celgene

After all, Celgene has a strong track record of generating top-line growth in excess of 20% per year, and the company has successfully expanded the labels of its core cancer drugs Revlimid and Abraxane over the years.

With Revlimid's sales starting to cool off to some degree and rising R&D costs taking a toll on its bottom-line in the fourth quarter, biotech investors seemed to think it was time to start moving to the sidelines -- causing Celgene's shares and the IBB to head lower in January. 

Now what: Celgene has historically sported one of the highest premiums among large-cap biotechs, as evidenced by its 12-month, trailing price-to-earnings ratio of 51. Unfortunately, the market seems to be signaling that it's no longer willing to pay such stately premiums -- even for companies generating industry-leading levels of revenue growth like Celgene. 

The cold, hard truth is that the market is shrouded in fear at the moment because of the strong dollar, the downturn in China, and the U.S. presidential election. That's why Celgene and the broader IBB ETF may struggle to break out of their funk in 2016.

The good news is that Celgene has a stellar clinical pipeline, chock-full of potential blockbusters  spanning a diversity of indications. So, once these current headwinds fade away, this biotech should be poised to return to its winning ways, making it a great stock to own for the long haul.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Corporation Stock Quote
Celgene Corporation
CELG
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
IBB
$123.29 (0.39%) $0.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.